Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Guangzhou Innogen Pharmaceutical Group Co Days Payable?
Guangzhou Innogen Pharmaceutical Group CoHKSE:02591 +5.26%9 Days Payable is 3,865.91 as of Dec. 2025, which is 2% below its 10-year median of 3,953.59. GuruFocus rates HKSE:02591 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review. Among 703 Biotechnology companies, Guangzhou Innogen Pharmaceutical Group Co ranks better than 92.89% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co Days Payable Chart
Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend
Dec23
Dec24
Dec25
Days Payable
0.00
0.00
3,953.59
Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Days Payable
0.00
0.00
0.00
3,451.00
3,865.91
HKSE:02591 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Guangzhou Innogen Pharmaceutical Group Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangzhou Innogen Pharmaceutical Group Co Days Payable vs Biotechnology Industry
Guangzhou Innogen Pharmaceutical Group Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a Days Payable of 3,865.91 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. This is near median its historical median of 3,953.59. Over the past decade, Guangzhou Innogen Pharmaceutical Group Co's Days Payable has ranged from 3,787.58 to 3,953.59. According to the industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #50 out of 703 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Guangzhou Innogen Pharmaceutical Group Co's Days Payable too high?
Guangzhou Innogen Pharmaceutical Group Co's current Days Payable of 3,865.91 is near median its 10-year median of 3,953.59. Over the past 10 years, this metric has ranged from a low of 3,787.58 to a high of 3,953.59. The Biotechnology industry median Days Payable is 112.61. Guangzhou Innogen Pharmaceutical Group Co's value of 3,865.91 is 3333% above this industry median. Based on the distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #50 out of 703 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Guangzhou Innogen Pharmaceutical Group Co ranks #50 out of 703 companies for Days Payable. This places Guangzhou Innogen Pharmaceutical Group Co in the top 7% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.61. Guangzhou Innogen Pharmaceutical Group Co's value of 3,865.91 is 3333% above this benchmark. Historically, Guangzhou Innogen Pharmaceutical Group Co's own Days Payable has ranged from 3,787.58 to 3,953.59 over the past decade. While the company's 10-year median is 3,953.59 vs. the industry median of 112.61, Guangzhou Innogen Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.61, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangzhou Innogen Pharmaceutical Group Co's current Days Payable of 3,865.91 is 3333% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Guangzhou Innogen Pharmaceutical Group Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangzhou Innogen Pharmaceutical Group Co's current Days Payable is 3,865.91, which is near median its own 10-year median of 3,953.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current Days Payable of 3,865.91. The current Days Payable is 3,865.91, which is near median its 10-year median of 3,953.59 and 3333% above the Biotechnology industry median of 112.61. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current Days Payable is 3,865.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score
Get the complete analysis for HKSE:02591
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02591 has been successfully added to your 
